Arrowhead CMO reports planned sale of 10,000 ARWR shares at $20

Rhea-AI Filing Summary

James C. Hamilton, Chief Medical Officer of Arrowhead Pharmaceuticals (ARWR), reported two open-market sales of common stock executed under a Rule 10b5-1 trading plan. On 08/13/2025 he sold 611 shares at $20 per share and on 08/15/2025 he sold 9,389 shares at $20 per share, for total reported disposals of 10,000 shares at $20 each. After these transactions he beneficially owned 262,122 shares, down from 271,511 shares prior to the sales. The filing notes that the post-transaction total includes previously reported shares underlying restricted stock units, some of which remain subject to vesting conditions.

Insights

Securities Analyst

TL;DR: Insider executed routine Rule 10b5-1 sales totaling 10,000 shares at $20; holdings modestly reduced.

The transactions are disclosed as sales under a pre-established 10b5-1 plan, indicating they were executed pursuant to a pre-set schedule rather than ad hoc timing. Aggregate disposals equal 10,000 shares at $20 per share. Beneficial ownership after the sales is reported at 262,122 shares and includes restricted stock units that remain partially unvested. From a market-impact perspective these appear to be orderly, planned disposals rather than opportunistic trades; the filing does not present other material changes to compensation or control.

Corporate Governance Expert

TL;DR: Disclosure follows standard Section 16 reporting and cites a 10b5-1 plan; no governance red flags stated.

The Form 4 properly identifies the reporting person, relationship to the issuer as Chief Medical Officer, and provides transaction dates, quantities, and prices. The filing explicitly states the sales were made under a 10b5-1 plan and clarifies inclusion of restricted stock units in post-transaction beneficial ownership. There are no statements of amendments, unusual derivative transactions, or changes in reporting status. Based solely on the filing, there are no governance issues disclosed.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hamilton James C

(Last) (First) (Middle)

177 EAST COLORADO BLVD

SUITE 700

(Street)

PASADENA CA 91105

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARROWHEAD PHARMACEUTICALS, INC. [ ARWR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/13/2025		S(1)		611	D	$20	271,511(2)	D
Common Stock	08/15/2025		S(1)		9,389	D	$20	262,122(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

2. Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

Remarks:

	/s/James Hamilton	08/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did ARWR Chief Medical Officer James C. Hamilton report?

He reported sales of 611 shares on 08/13/2025 and 9,389 shares on 08/15/2025, both at $20 per share, totaling 10,000 shares.

Were the sales by the ARWR insider part of a trading plan?

Yes. The filing states the shares were sold pursuant to a 10b5-1 trading plan adopted by the reporting person.

How many ARWR shares did the reporting person own after the transactions?

The filing reports beneficial ownership of 262,122 shares following the reported transactions, which includes restricted stock units some of which remain subject to vesting.

Did the Form 4 report any derivative transactions or amendments?

No. The filing shows only non-derivative common stock sales and does not indicate any amendments or derivative security transactions.

What is the reporting person's role at Arrowhead (ARWR)?

The Form 4 identifies the reporting person as the company's Chief Medical Officer.